Almac Group Appoints Vice President of Small Molecule API
October 7, 2020
Dan has been a key member of the company’s global Chemical Development and Scale-up team for the past 17 years. His unique knowledge, strong technical background and delivery track record has driven significant innovation in our service offering during this time and, in recent years, he has become increasingly involved in customer management, business performance assessment and business strategy.
Dr Stephen Barr, President & Managing Director, Almac Sciences, commented “Dan’s experience, credentials and working relationship with both his team, and the wider Business Unit, makes him a well-respected leader. This promotion is well deserved and I, and the rest of the Sciences’ Executive team, look forward to working with him in his new role.”
Prior to joining Almac in 2003, Dan completed a BSc at the University of Sheffield, a PhD at the University of Louvain-la-Neuve (Belgium) and held a Post-doctoral research position at the University of Oxford.
In addition, he has almost a decade of experience in various process development roles with a UK based chemical services company.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia. To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com